{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T04:36:40Z","timestamp":1789015000901,"version":"build-2803163510"},"reference-count":22,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2018,2,10]],"date-time":"2018-02-10T00:00:00Z","timestamp":1518220800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","award":["Fellowship Program 2016"],"award-info":[{"award-number":["Fellowship Program 2016"]}],"id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2018,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Patients with a Ph\u2010negative myeloproliferative neoplasm (MPN) may harbor or develop lymphoproliferative disorders (LPD), however, the clinical and molecular determinants of MPN and LPD co\u2010occurrence are still uncertain. To systematically pool the available knowledge, we conducted a scoping review of literature published since January 2005 and analyzed single\u2010patient clinical data from 50 papers reporting 214 individuals harboring both MPN and LPD. Patients had been diagnosed essential thrombocythemia (44%), polycythemia vera (29%), or myelofibrosis (23%) at a median age of 67 years (26\u201094): half of them incurred a LPD after a median of 72 months from MPN diagnosis, while in 20% the LPD diagnosis was antecedent or synchronous. Patients mainly incurred indolent LPD, particularly chronic lymphocytic leukemia (CLL), while aggressive lymphomas and multiple myeloma were a relevant portion of the LPDs occurring in the follow\u2010up of MPN. CLL was preferentially diagnosed in PV patients and was associated with a very high male\u2010to\u2010female ratio, as well as an older age at MPN diagnosis. On converse, multiple myeloma was rarely reported in PV patients and was preferentially diagnosed in female patients not harboring the JAK2 V617F mutation. Based on the 46 cases reporting follow\u2010up data, median survival after MPN diagnosis was 96 months. This thorough review of published evidence confirms that LPD are relevant clinical events in the history of MPN patients. Controlled studies are needed to better refine individuals at higher risk of developing LPD, to support surveillance programs and to avoid therapies possibly favoring LPD.<\/jats:p>","DOI":"10.1002\/ajh.25049","type":"journal-article","created":{"date-parts":[[2018,1,29]],"date-time":"2018-01-29T19:57:33Z","timestamp":1517255853000},"page":"698-703","source":"Crossref","is-referenced-by-count":38,"title":["Lymphoproliferative disorders in patients with chronic myeloproliferative neoplasms: A systematic review"],"prefix":"10.1002","volume":"93","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7615-0572","authenticated-orcid":false,"given":"Monia","family":"Marchetti","sequence":"first","affiliation":[{"name":"Hematology Unit, Oncology Department Cardinal Massaia Hospital, Corso Dante 202 14100 Asti Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Carobbio","sequence":"additional","affiliation":[{"name":"Research Foundation FROM, Papa Giovanni XXIII Hospital, Piazza OMS 1 24127 Bergamo Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrica","family":"Capitoni","sequence":"additional","affiliation":[{"name":"Research Foundation FROM, Papa Giovanni XXIII Hospital, Piazza OMS 1 24127 Bergamo Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2747-6327","authenticated-orcid":false,"given":"Tiziano","family":"Barbui","sequence":"additional","affiliation":[{"name":"Research Foundation FROM, Papa Giovanni XXIII Hospital, Piazza OMS 1 24127 Bergamo Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,2,10]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-016-2730-y"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.57.6652"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-09-0353"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2010.033191"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.42.1925"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-04-348755"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(15)00092-7"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2015.1071492"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12410"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.5306\/wjco.v7.i4.324"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2010.529207"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.20"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-14-0129"},{"key":"e_1_2_5_15_1","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-15-0805"},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms10933"},{"key":"e_1_2_5_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2843"},{"key":"e_1_2_5_18_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.16381"},{"key":"e_1_2_5_19_1","first-page":"1643","article-title":"JAK2\u2010inhibitior therapy associated lymphomas in myelofibrosis: distinct clinic\u2010pathological features recapitulated in a mouse model","volume":"130","author":"Tripolt S","year":"2017","journal-title":"Blood."},{"key":"e_1_2_5_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.29933"},{"key":"e_1_2_5_21_1","first-page":"1634","article-title":"Relative lymphocytosis is associated with improved outcome in myelofibrosis and may account for the favorable prognosis of the CALR mutation","volume":"130","author":"Kuykendall A","year":"2017","journal-title":"Blood."},{"key":"e_1_2_5_22_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0090299"},{"key":"e_1_2_5_23_1","first-page":"1525","article-title":"Lympho\u2010 and myeloproliferative malignancies occurring in the same host: description of a nationwide discovery cohort","volume":"130","author":"Holst JM","year":"2017","journal-title":"Blood."}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fajh.25049","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.25049","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,10]],"date-time":"2023-09-10T04:06:20Z","timestamp":1694318780000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.25049"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,10]]},"references-count":22,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["10.1002\/ajh.25049"],"URL":"https:\/\/doi.org\/10.1002\/ajh.25049","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,10]]}}}